← Back to Search

Beta-3 Adrenoceptor Agonist

Treatment Group for Overactive Bladder

Phase 4
Waitlist Available
Led By Anil Kapoor, MD, FRCSC
Research Sponsored by St. Joseph's Healthcare Hamilton
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up timeline: 4 weeks
Awards & highlights

Study Summary

This trial is testing a new OAB treatment combining a β3-adrenoceptor agonist (mirabegron) with an α-blocker. The goal is to see if this is a safe and effective treatment for OAB symptoms in male patients with BPH.

Eligible Conditions
  • Enlarged Prostate
  • Overactive Bladder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~timeline: 4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and timeline: 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
International Prostate Symptom Score (IPSS)
Overactive Bladder Symptom Score (OABSS)
Quality of Life Score (QoLS)
Secondary outcome measures
Adverse Events

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Treatment GroupActive Control2 Interventions
(Mirabegron + Tamsulosin)
Group II: Control GroupPlacebo Group1 Intervention
(Placebo + Tamsulosin)

Find a Location

Who is running the clinical trial?

St. Joseph's Healthcare HamiltonLead Sponsor
196 Previous Clinical Trials
25,344 Total Patients Enrolled
Anil Kapoor, MD, FRCSCPrincipal InvestigatorMcMaster University
3 Previous Clinical Trials
70 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.
Anil Kapoor 2021. "Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02279615.
All > Benign Prostatic Hyperplasia > Bph
~60 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top